In an HIV-positive patient, at what CD4 count should a urine TB-LAM test be performed?

Urine TB-LAM Testing CD4 Threshold

Perform urine TB-LAM testing in HIV-positive patients with CD4 count <200 cells/µL who have signs and symptoms of tuberculosis.

CD4-Based Testing Thresholds

The evidence strongly supports a CD4-stratified approach to urine TB-LAM testing:

Primary Indication: CD4 <100 cells/µL

• Highest diagnostic yield: LAM sensitivity reaches 87% in patients with CD4 ≤100 cells/µL 1
• The test identifies 59% of culture-positive TB cases in this severely immunosuppressed group 2
• FujiLAM (newer generation) shows 69% sensitivity at CD4 <200 cells/µL, substantially better than the older AlereLAM at 52% 3

Extended Indication: CD4 100-199 cells/µL

• LAM remains clinically valuable in this range, with sensitivity of 63% for FujiLAM 1
• Critical finding: LAM identified an additional 27-29% of TB cases in patients with CD4 100-199 cells/µL who would have been missed by microscopy or Xpert alone 4
• Patients in this range who were LAM-positive but untreated had 2.57 times higher mortality risk 4

Limited Value: CD4 >200 cells/µL

• Sensitivity drops to 44% with FujiLAM and only 11% with AlereLAM 1
• Testing above this threshold has minimal diagnostic yield

Clinical Algorithm

Test urine TB-LAM when ALL of the following are present:

• HIV-positive status confirmed
• CD4 count <200 cells/µL (prioritize if <100 cells/µL)
• TB symptoms present (cough, fever, weight loss, night sweats)
• Ambulatory or hospitalized setting

Additional high-yield scenarios regardless of exact CD4:

• Seriously ill patients with advanced HIV
• When sputum cannot be obtained
• Mycobacteremia suspected (strongly associated with LAM positivity) 2

Key Performance Characteristics

The newer FujiLAM assay substantially outperforms the older AlereLAM:

• Overall sensitivity: 71% vs 35% 1
• Specificity: Both maintain >90% specificity 3, 1
• Incremental diagnostic yield: LAM adds 35-38% more TB diagnoses when combined with Xpert or microscopy 4

Critical Pitfalls to Avoid

1. Don't wait for CD4 <100 cells/µL exclusively: Evidence shows meaningful benefit up to CD4 <200 cells/µL, where 50% of confirmed TB cases were diagnosed only through LAM 4

2. Don't skip LAM if Xpert is available: LAM identifies different patient populations—50% of LAM-positive patients would be missed by Xpert alone 4

3. Assay variability matters: FujiLAM lot-to-lot variability has been documented (sensitivity 48-76%, specificity 77-98%), though this needs resolution before widespread clinical use 3

4. Don't use in asymptomatic patients: Even with advanced HIV, testing is indicated primarily for symptomatic individuals or those with clinical suspicion of TB 3

The evidence consistently demonstrates that CD4 <200 cells/µL is the practical threshold for urine TB-LAM testing, with maximum benefit at CD4 <100 cells/µL, in HIV-positive patients with TB symptoms 3, 1, 4, 2.